total number of show in page
New Flow diverter Surpass Evolve

New Flow diverter Surpass Evolve

Procedures were performed under general anesthesia by three authors (VMP, TK, HR) with extensive experience with FDs and SS for the treatment of aneurysms. Dual antiplatelet therapy (aspirin and either ticagrelor or Plavix (clopidogrel)) was initi-ated 3 days before the procedure and continued for at least 6 months. Intravenous heparin was administered intraoperatively and titrated to maintain an activated clotting time between 250 and 300 s. For femoral access, an 0.088" guiding sheath was placed in the internal carotid or subclavian artery. A 115 cm 0.058" Catalyst 5 (Cat 5, Stryker Neurovascular, Michigan, USA) was used as intermediate catheter. For radial access, a 0.071" guiding catheter was navigated into the parent vessel and a Phenom+ (Medtronic, Irvine, California, USA) used as inter-mediate catheter. An 0.027" XT-27 microcatheter was placed distal to the aneurysm and used to deliver the FD. The treat-ment strategy was to deploy a single FD, but if multiple implants were indicated, devices were telescopically deployed from distal to proximal. Adjunctive coils were placed according to oper-ator preference. Correct FD wall apposition was confirmed by VasoCT. Patients with no complications were discharged after 24 hours of observation.

28 Aug 1399
Abbott: A HISTORY OF NURTURING HUMAN POTENTIAL

Abbott: A HISTORY OF NURTURING HUMAN POTENTIAL

About The Abbott Company and Professor Amplatz

6 Jan 1395
Terumo Showcases Radial Access Portfolio at American College of Cardiology Conference

Terumo Showcases Radial Access Portfolio at American College of Cardiology Conference

Two years after MATRIX trial demonstrates benefits, company continues commitment to drive a radial first treatment strategy for coronary interventions

6 Jan 1395
total number of show in page